2-(Fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D<sub>1</sub> Receptor for Parkinson’s Disease-Reference-Cited by-同舟云学术

2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D₁ Receptor for Parkinson’s Disease

Published:2022-08-31 Issue:18 Volume:65 Page:12256-12272
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

García-Cárceles Javier¹^ORCID,Vázquez-Villa Henar¹^ORCID,Brea José²^ORCID,Ladron de Guevara-Miranda David³,Cincilla Giovanni⁴^ORCID,Sánchez-Martínez Melchor⁴^ORCID,Sánchez-Merino Anabel¹,Algar Sergio¹^ORCID,Teresa de los Frailes María⁵,Roberts Richard S.⁵,Ballesteros Juan A.⁶,Rodríguez de Fonseca Fernando³,Benhamú Bellinda¹^ORCID,Loza María I.²⁵^ORCID,López-Rodríguez María L.¹^ORCID

Affiliation:

1. Departamento de Química Orgánica, Universidad Complutense de Madrid, E-28040 Madrid, Spain

2. Biofarma Research Group, USEF Screening Platform, CIMUS, USC, E-15782 Santiago de Compostela, Spain

3. Instituto de Investigación Biomédica de Málaga (IBIMA), E-29010 Málaga, Spain

4. Molomics S.L., Parc Científic de Barcelona, Baldiri Reixac 4-8, E-08028 Barcelona, Spain

5. Fundación Kærtor, Edificio EMPRENDIA, Planta 2, Oficina 4. Campus Vida, E-15706 Santiago de Compostela, Spain

6. Vivia Biotech S.L., Parque Científico de Madrid, E-28760 Madrid, Spain

Funder

Universidad Complutense de Madrid

Ministerio de Ciencia e Innovaci?n

European Regional Development Fund

Axencia Galega de Innovaci?n

Instituto de Salud Carlos III

Kaertor Foundation

Janssen/Johnson and Johnson Innovation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00949

Reference73 articles.

1. Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson’s disease

2. Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuospatial memory alteration

3. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists

4. The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease

5. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?;Pharmaceutics;2024-05-24

2. Asymmetric synthesis of sulfoximines, sulfonimidoyl fluorides and sulfonimidamides enabled by an enantiopure bifunctional S(VI) reagent;Nature Chemistry;2024-01-18

3. Key aspects of modern GPCR drug discovery;SLAS Discovery;2024-01